# Pharmacokinetics, Safety, and Tolerability Study of the Pen and PFS of SB5 in Healthy Subjects

> **NCT02326233** · PHASE1 · COMPLETED · sponsor: **Samsung Bioepis Co., Ltd.** · enrollment: 190 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** Pen of SB5
- **BIOLOGICAL:** PFS of SB5

## Key facts

- **NCT ID:** NCT02326233
- **Lead sponsor:** Samsung Bioepis Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 190 (ACTUAL)
- **Last updated:** 2019-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02326233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02326233, "Pharmacokinetics, Safety, and Tolerability Study of the Pen and PFS of SB5 in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02326233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*